Historical and Projected Surface Temperature over India during the 20th and 21st century.

Surface Temperature (ST) over India has increased by ~0.055 K/decade during 1860-2005 and follows the global warming trend. Here, the natural and external forcings (e.g., natural and anthropogenic) responsible for ST variability are studied from Coupled Model Inter-comparison phase 5 (CMIP5) models during the 20th century and projections during the 21st century along with seasonal variability. Greenhouse Gases (GHG) and Land Use (LU) are the major factors that gave rise to warming during the 20th century. Anthropogenic Aerosols (AA) have slowed down the warming rate. The CMIP5 projection over India shows a sharp increase in ST under Representative Concentration Pathways (RCP) 8.5 where it reaches a maximum of 5 K by the end of the 21st century. Under RCP2.6 emission scenarios, ST increases up to the year 2050 and decreases afterwards. The seasonal variability of ST during the 21st century shows significant increase during summer. Analysis of rare heat and cold events for 2080-2099 relative to a base period of 1986-2006 under RCP8.5 scenarios reveals that both are likely to increase substantially. However, by controlling the regional AA and LU change in India, a reduction in further warming over India region might be achieved

In vitro Evaluation of Some Different Brands of Alprazolam Tablets

Alprazolam belongs to a group of medicines called benzodiazepines. These medicines are thought to work by their action on brain chemicals. Alprazolam has sedative effects and is used to treat: (i) Anxiety and (ii) Panic attacks. The results obtained in this research by various HPLC analyses and other physicochemical tests have shown that alprazolam tablets manufactured by Dr. Abidi and Poursina Pharmaceutical Companies of Iran have the standard limits acceptable by the internationally well known Pharmacopoeia such as USP and can satisfy the needs of patients quite well and are quite comparable with Xanax® of USA and Apo-Alpraz® of Canada

Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial

As no specific pharmacological treatment has been validated for use in coronavirus disease 2019 (COVID-19), we aimed to assess the effectiveness of azithromycin (AZM) in these patients at a referral centre in Iran. An open-label, randomised controlled trial was conducted on patients with laboratory-confirmed COVID-19. A total of 55 patients in the control group receiving hydroxychloroquine (HCQ) and lopinavir/ritonavir (LPV/r) were compared with 56 patients in the case group who in addition to the same regimen also received AZM. Patients with prior cardiac disease were excluded from the study. Furthermore, patients from the case group were assessed for cardiac arrythmia risk based on the American College of Cardiology (ACC) risk assessment for use of AZM and HCQ. The main outcome measures were vital signs, SpO2 levels, duration of hospitalisation, need for and length of intensive care unit admission, mortality rate and results of 30-day follow-up after discharge. Initially, there was no significant difference between the general conditions and vital signs of the two groups. The SpO2 levels at discharge were significantly higher, the respiratory rate was lower and the duration of admission was shorter in the case group. There was no significant difference in the mortality rate between the two groups. Patients who received AZM in addition to HCQ and LPV/r had a better general condition. HCQ+AZM combination may be beneficial for individuals who are known to have a very low underlying risk for cardiac arrhythmia based on the ACC criteria. © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherap